

Completion of first customer site installation of new **EasyScreen™** Respiratory Virus Detection Kit

Sydney, Australia, 10 April 2015: Molecular diagnostics (MDx) company Genetic Signatures Limited is pleased to announce the completion of the first customer site installation of its newly released **EasyScreen™ Respiratory Virus Detection Kit** at St Vincent's Pathology (SydPath) in Sydney, New South Wales, Australia.

SydPath is a fully accredited registered pathology laboratory service located within the St Vincent's Hospital Campus, and is an existing customer of the company's **EasyScreen™ Enteric Pathogen Assays** that screen for a wide range of infectious agents including viral, bacterial and protozoan agents. The installation follows the company's initial commercial sales media release on 10 March 2015.

The **EasyScreen™ Respiratory Virus Detection Kit** was developed over an 18 month period and leverages the company's proprietary MDx **3Base™** platform technology. The **EasyScreen™ Respiratory Virus Detection Kit** simultaneously identifies 15 of the most common respiratory viral infections and contains the necessary reagents to detect multiple viral gene targets, allowing rapid screening of a large number of viral pathogens. The respiratory multiplex assay is initially available in research use form.

Genetic Signatures' CEO Dr. John Melki said: "This first installation has been very successful and we look forward to SydPath's participation in the final testing of the respiratory kit, before its registration as a diagnostic product. The **EasyScreen™ Respiratory Virus Detection Kit** has been in development for 18-months and was easily integrated into the **EasyScreen™** Enteric workflows already in place at SydPath."

SydPath Senior Hospital Scientist Dr Damien Stark commented on the announcement saying that: "During initial beta-testing, the **EasyScreen™ Respiratory Virus Detection Kit** was found to detect significantly more viral respiratory infections compared to our current molecular methodology. We look forward to final testing of the product and, subsequently, using the kit in diagnostic form".

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Company	Media and Investor Relations
John Melki Chief Executive Officer john@geneticsignatures.com T: +61 2 9870 7580	Peter Taylor Investor Relations peter@nwrcommunications.com.au T: +61 412 036 231
Robert Birrell Chief Financial Officer rob@geneticsignatures.com T: +61 2 9870 7580	

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, *3Base™*. Founded in 2001 by the late Dr Geoffrey Grigg, the former Chief of Molecular Biology at CSIRO, Genetic Signatures has released a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. MDx is a modern technique increasingly used by hospitals and pathology laboratories to detect specific sequences of the genome, the DNA or RNA that define an organism. Genetic Signatures' proprietary MDx *3Base™* platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening. As the spread of infectious diseases around the world continues to grow, the Company plans to launch additional products for the detection of pathogens associated with MRSA, sexual health infections, tuberculosis and meningitis.

About SydPath: SydPath is a fully accredited NATA/RCPA/TGA registered laboratory offering a wide range of pathology services. As a teaching hospital laboratory located within the St Vincent's Hospital Campus, SydPath offers a market-leading range of onsite testing and expert consultative support. Extensive experience at the forefront of diagnostic pathology and ongoing commitment to research and scientific development enables SydPath to provide a service based on the most recent advances in scientific pathology and laboratory technology. SydPath offers services to:

- St. Vincent's Hospital and St Vincent's Private Hospital
- General practitioners
- Specialists
- Private and Public sector laboratories
- Hospital research programs

SydPath also provides specialised services tailored to the needs of the pharmaceutical and biotechnology industries for their clinical trial & research programs.

About Viral Respiratory Infections: According to the World Health Organisation, respiratory viral infections are responsible for the deaths of an estimated 3.9 million people per year, and are one of the top five causes of mortality worldwide particularly in children, the elderly and immunocompromised persons. In addition to increasing the risk of secondary bacterial infections, respiratory viruses cause an enormous burden to health systems by way of direct medical expenses and indirect productivity losses¹. Rapid identification of viral respiratory infections is critical in initiating antiviral treatment and limiting the spread of the infection.

¹ World Health Organisation (2015), Battle against Respiratory Viruses (BRaVe) initiative, http://www.who.int/influenza/patient_care/clinical/brave/en/